Pharmaceuticals, Biotechnology & Life Sciences

InflaRx NV: German biopharma firm advancing monoclonal antibody drugs for inflammatory diseases, with volatile share price yet strong investor confidence and upcoming 2026 investor conference.

Viatris’s FDA‑accepted MR‑141 could unlock a new, non‑invasive presbyopia market, diversifying earnings and boosting stock value—will it succeed?

BioCardia Inc. (BIOC) is a U.S. biotech focused on cardiovascular therapies, with a $12 M market cap and current negative P/E. No new news yet—watch regulatory filings and earnings for growth clues.

Read how Astellas Pharma’s $1.7 billion partnership with Vir Biotechnology could change prostate cancer treatment with the PSMA‑targeted VIR‑5500 dual‑masked T‑cell engager, boosting oncology innovation.

Rocket Pharmaceuticals is pushing gene‑therapy breakthroughs for rare pediatric diseases, trading around $4, with a 52‑week high of $9.84, a P/B of 1.30, and investor‑focused engagements at major healthcare conferences.

Novartis releases real‑world evidence boosting Pluvicto’s use for metastatic prostate cancer and faces shareholder‑driven CEO compensation review.

Repligen Corp’s Q4 2025 results show 18% revenue lift to $198 M and 14% organic growth, while 2026 guidance forecasts $810‑$840 M revenue and margin expansion.

BioNTech sues Moderna in Delaware over mRNA patent, sparking a new legal battle amid vaccine efficacy gains and a growing oncology pipeline.

Johnson & Johnson’s latest legal battles, Blackstone partnership, and TREMFYA data reveal a resilient portfolio and rising analyst targets, keeping investors confident in its future growth.

Ocugen’s clinical‑stage biopharma journey: regenerative joint therapy, 2026 stock trends, upcoming earnings call, and investor outlook for biotech growth.